---
title: "J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286414735.md"
description: "J.P. Morgan analyst Anupam Rama has maintained a Buy rating on Erasca (ERAS) with a price target of $23.00, while the stock closed at $10.46. Rama has an average return of 23.7% and a success rate of 52.03% on his recommendations. Mizuho Securities also issued a Buy rating for Erasca, but Bank of America Securities reiterated a Sell rating on the same day."
datetime: "2026-05-14T12:12:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286414735.md)
  - [en](https://longbridge.com/en/news/286414735.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286414735.md)
---

# J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Erasca, with a price target of $23.00. The company’s shares closed yesterday at $10.46.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Travere Therapeutics, and Erasca. According to TipRanks, Rama has an average return of 23.7% and a 52.03% success rate on recommended stocks.

In addition to J.P. Morgan, Erasca also received a Buy from Mizuho Securities’s Joseph Catanzaro in a report issued on May 12. However, on the same day, Bank of America Securities reiterated a Sell rating on Erasca (NASDAQ: ERAS).

### Related Stocks

- [ERAS.US](https://longbridge.com/en/quote/ERAS.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)
- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)